Illumina Files New Patent Infringement Suit
News May 19, 2015
Illumina has announced that the company has filed a new patent infringement suit against Ariosa Diagnostics, Inc. and its parent company, Roche Molecular Systems, Inc. Illumina is seeking all available remedies.
The new suit, filed in the U.S. District Court for the Northern District of California, is based on Ariosa’s infringement of U.S. Patent No. 7,955,794 (the ‘794 patent), entitled “Multiplex Nucleic Acid Reactions.” The suit is focused on Ariosa’s Microarray-based version of its Harmony™ Prenatal Test.
Illumina and its wholly owned subsidiary, Verinata Health, Inc., previously filed suits in the U.S. District Court for the Northern District of California against Ariosa accusing its Sequencing-based version of the Harmony Prenatal Test of infringing the ‘794 patent and U.S. Patent No. 8,296,076 and U.S. Patent No. 8,318,430. Those previous suits remain pending.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.